Year | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|
Iran population | 89613176.84 | 90688534.96 | 91776797.38 | 92878118.95 | 93992656.38 |
ADHD patients | 13979655.59 | 14147411.45 | 14317180.39 | 14488986.56 | 14662854.39 |
Market share of methylphenidate | 0.27 | 0.12 | 0.12 | 0.10 | 0.09 |
Market share of atomoxetine | 0.35 | 0.44 | 0.43 | 0.46 | 0.46 |
Market share of clonidine | 0.39 | 0.44 | 0.45 | 0.44 | 0.46 |
Market share of lisdexamfetamine | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 |
Market share of lisdexamfetamine (IF it is covered by insurance) | 0.01 | 0.03 | 0.05 | 0.08 | 0.11 |
Scenario 1(without Lisdexamfetamine) ($) | 357412 | 359048 | 365994 | 366395 | 372724 |
Scenario 2 (with lisdexamfetamine) ($) | 368566 | 421487 | 430407 | 433828 | 443879 |
Scenario 3 (with lisdexamfetamine and it is covered by insurance) ($) | 368566 | 421483 | 430,397 | 433808 | 443849 |
Financial impact in scenarios 1&2 ($) | 11154 | 62439 | 64413 | 67432 | 71154 |
Financial impact in scenarios 1&3 ($) | 11154 | 62434 | 64403 | 67412 | 71124 |